FilingSEC EDGAR8-K
Nexalin Technology SVP of Quality, Regulatory, and Clinical Affairs Departs
· SEC accepted
StageExecutive Departure
Filing content
The Senior Vice President of Quality, Regulatory, and Clinical Affairs departed the company on August 28, 2026, and entered into a separation agreement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…